移植后胰岛细胞所处的生理环境与原位胰腺中的完全不同，因此移植后胰岛细胞的存活及功能表达与之密切相关。利用生物材料制备人造骨架（scaffold），可在组织再生初期模拟一个类似细胞外骨架的微环境，为细胞存活和生长提供良好平台。前期实验我们利用电纺织技术（electrospinning）制备新型人造骨架，并且初步证明了该人造骨架可促进移植后胰岛细胞的生长。同时我们首次发现了阿格列汀（alogliptin）可改善胰岛移植效果。本课题拟在这些实验基础上，进一步构建阿格列汀释放型人造骨架用于包裹胰岛细胞，并监测移植后胰岛细胞存活率以及胰岛功能表达的变化。通过人造骨架为植入的胰岛提供一个仿真微环境，同时作为药物投递的媒介，连续、定点释放alogliptin，从而降低总体用药量并减少用药带来的副作用，以期提高胰岛移植的临床效果。

The physiological environments where the islets transplanted into are completely different from the orthotopic pancreas. This influences the survival rate and function of the islet transplantation. Scaffold made by biomaterials can mimic an extracellular microenvirement at the early regeneration stage for cells to survive and regenerate. We previously used electrospinning to make new scaffold, and proved that it could improve the effects of islet transplantation. Meanwhile, our results showed that alogliptin can also improve the outcome of islet transplantation. So this study aim to set up a alogliptin-delivered scaffold to improve the outcome of islet transplantation. Through providing a similar microenvirement and reduce the dosage of drugs, this new scaffold could hopefully improve the effect of islet transplantation.